Skyrizi Launch Skyrockets, Boosting AbbVie Hopes For Humira Successors
AbbVie’s balancing act sees Skyrizi/Rinvoq launches and strong hematologic cancer strength offset the continued erosion of Humira sales outside the US. Rinvoq gets off to a quick start in its US launch.
You may also be interested in...
AbbVie reported revenue growth during the second quarter, with products like Rinvoq and Skyrizi leading the charge. But Allergan, despite growth for Vraylar and Ubrelvy, pushed down overall performance.
AbbVie made only a slight adjustment to its earnings-per-share guidance despite expected Q2 downturn due to the pandemic. It sees Allergan’s aesthetic business as bouncing back quickly.
Despite Humira’s ex-US sales erosion, AbbVie reports strong launches for Skyrizi and Rinvoq, continued growth for hematological oncology franchise, and boasts it has a thriving R&D engine.